Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1957 1
1969 1
1975 4
1976 1
1977 4
1978 4
1979 2
1980 1
1981 3
1982 6
1983 8
1984 5
1985 8
1986 5
1987 8
1988 5
1989 11
1990 4
1991 7
1992 10
1993 17
1994 15
1995 7
1996 4
1997 17
1998 18
1999 22
2000 19
2001 16
2002 10
2003 7
2004 7
2005 3
2006 9
2007 11
2008 11
2009 10
2010 8
2011 13
2012 14
2013 11
2014 8
2015 6
2016 3
2017 3
2018 2
2019 2
2020 5
2021 3
2022 6
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

382 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of Autologous Stem Cell Transplantation for Myeloma Patients with Suboptimal Response: A Multicenter Retrospective Analysis.
Suzuki K, Shimazu Y, Minakata D, Ikeda T, Takahashi H, Tsukada N, Kanda Y, Doki N, Nishiwaki K, Miwa A, Sawa M, Kataoka K, Hiramoto N, Ota S, Itagaki M, Ichinohe T, Atsuta Y, Yano S, Kawamura K; working group of the Japan Society for Transplantation and Cellular Therapy. Suzuki K, et al. Among authors: miwa a. Transplant Cell Ther. 2023 Nov;29(11):688.e1-688.e13. doi: 10.1016/j.jtct.2023.08.006. Epub 2023 Aug 11. Transplant Cell Ther. 2023. PMID: 37574125
Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma.
Togano T, Andoh S, Komuro M, Mitsui Y, Itoi S, Hirai R, Nakamura M, Tanimura A, Sekine R, Takeshita M, Miwa A, Hagiwara S. Togano T, et al. Among authors: miwa a. Intern Med. 2022 Nov 15;61(22):3329-3334. doi: 10.2169/internalmedicine.9097-21. Epub 2022 Apr 23. Intern Med. 2022. PMID: 35466165 Free PMC article.
Antiviral effect and safety of nafamostat mesilate in patients with mild early-onset COVID-19: An exploratory multicentre randomized controlled clinical trial.
Okugawa S, Ikeda M, Kashiwabara K, Moritoyo T, Kohsaka T, Shimizu T, Hagiya H, Hasegawa K, Otsuka F, Miwa A, Kisimoto N, Mizoguchi A, Imamura A, Ikeuchi K, Tsutsumi T, Jubishi D, Hashimoto H, Okamoto K, Harada S, Inoue JI, Seto Y, Moriya K. Okugawa S, et al. Among authors: miwa a. Int J Antimicrob Agents. 2023 Sep;62(3):106922. doi: 10.1016/j.ijantimicag.2023.106922. Epub 2023 Jul 8. Int J Antimicrob Agents. 2023. PMID: 37429450 Free article. Clinical Trial.
A Case of polychondritis-onset refractory organizing pneumonia with cytopaenia diagnosed as VEXAS syndrome: the disease course of 7 years.
Sakuma M, Tanimura A, Yasui S, Ishiguro K, Kobayashi T, Ohshiro Y, Miyazaki H, Minamimoto R, Okafuji T, Shimozawa K, Ogura G, Miwa A, Yamashita H, Kaneko H. Sakuma M, et al. Among authors: miwa a. Rheumatology (Oxford). 2021 Oct 2;60(10):e356-e359. doi: 10.1093/rheumatology/keab349. Rheumatology (Oxford). 2021. PMID: 33839773 No abstract available.
382 results